All 12 Clinical Trial Participants Off External Insulin: Breakthrough in T1D Treatment with Tegoprubart
At the 2026 American Diabetes Association (ADA) Scientific Sessions, Eledon Pharmaceuticals unveiled groundbreaking results from an investigator-initiated trial of its experimental therapy, tegoprubart. The data revealed that all 12 participants with Type 1 Diabetes (T1D) have successfully discontinued external insulin use, marking a potential milestone in the treatment of the chronic condition. This development has sparked widespread interest among researchers, healthcare professionals, and patients, as it points to a novel approach that could redefine diabetes management.
What Happened: A New Frontier in Type 1 Diabetes Treatment
The trial, which focused on islet cell transplantation, involved 12 patients with T1D. Tegoprubart, a biologic therapy developed by Eledon Pharmaceuticals, was administered as part of a broader treatment protocol designed to restore the body’s ability to regulate blood glucose levels. According to the company’s presentation at the ADA conference, all participants achieved sustained glycemic control without the need for exogenous insulin. This outcome has been described as “remarkable” by the trial’s lead researchers, who emphasized the potential of the therapy to address the limitations of current treatments.
The trial’s results were presented during a session on innovative diabetes therapies, drawing attention from both the scientific community and the general public. The data highlighted that participants maintained stable hemoglobin A1c (HbA1c) levels, a key indicator of long-term blood sugar control, for at least six months post-treatment. Additionally, no serious adverse events were reported, suggesting that the therapy is well-tolerated.
Who Is Involved: Eledon Pharmaceuticals and the Broader Diabetes Community
Eledon Pharmaceuticals, a biotechnology company specializing in regenerative medicine, has been at the forefront of developing therapies for autoimmune and metabolic diseases. The company’s work on tegoprubart is part of a broader effort to harness the body’s natural mechanisms to combat chronic conditions. The trial was investigator-initiated, meaning it was led by independent researchers rather than the company itself, which adds a layer of credibility to the findings.
The participation of 12 patients in the trial underscores the collaborative nature of modern medical research. These individuals, who had previously relied on insulin injections or pumps, now represent a small but significant cohort of patients who have experienced a transformative change in their treatment. Their stories, while not explicitly detailed in the public announcement, highlight the personal impact of breakthroughs in diabetes care.
The ADA, which organized the conference, has long been a platform for sharing advancements in diabetes research. This year’s event, held in a hybrid format, brought together over 20,000 attendees, including clinicians, scientists, and patient advocates. The presentation of tegoprubart’s results was one of the most discussed topics, reflecting the high stakes and global interest in finding a cure for T1D.
Why It Matters: Implications for Patients and the Healthcare System
The implications of these findings are profound. For patients with T1D, the ability to eliminate insulin dependence could drastically improve quality of life. Insulin therapy, while life-saving, requires constant monitoring and carries risks
